---
layout: post
title: "Facility Readiness: Goal Date Decisions Under Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:03 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-21811
original_published: 2022-10-07 00:00:00 +0000
significance: 8.00
---

# Facility Readiness: Goal Date Decisions Under Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 07, 2022 00:00 UTC
**Document Number:** 2022-21811

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Facility Readiness: Goal Date Decisions Under GDUFA." This draft guidance provides information to applicants on how FDA will use information related to a facility's readiness for inspection as certified on Form FDA 356h to set a goal date for an original abbreviated new drug application (ANDA) submitted under the Federal Food, Drug, and Cosmetic Act. This guidance incorporates a program enhancement agreed upon by the Agency and industry as part of the negotiations relating to reauthorization of the Generic Drug User Fee Amendments (GDUFA) and as described in "GDUFA Reauthorization Performance Goals and Program Enhancements Fiscal Years 2023-2027" (GDUFA III commitment letter).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/07/2022-21811/facility-readiness-goal-date-decisions-under-generic-drug-user-fee-amendments-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-21811

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
